The latest edition of the Provider's Digest, HCPLive's monthly newsletter spotlighting regulatory decisions and pipeline news, is now live! In our August 2024 recap, we spotlight 14 FDA decisions and 7 announcements of new pipeline data. Be sure to subscribe for a recap of the therapies, companies, and individuals moving the needle in healthcare during the past month, delivered on the first Saturday of each new month! #FDANews #Healthcare #Medicine
HCPLive
Media Production
Cranbury, NJ 3,535 followers
Comprehensive clinical news that provide clinicians with up-to-date specialty and disease-specific information.
About us
HCPLive provides health care professionals with up-to-date specialty and disease-specific news, clinical information, and other resources to help provide better care to patients. On HCPLive.com, you will find in-depth conference coverage and information about upcoming meetings, perspective on regulatory news, and multimedia content featuring key opinion leaders. Get all the latest news on individual medical conditions in our "condition centers": • Cardiology • Endocrinology • Gastroenterology • Ophthalmology • Neurology • Pain Management • Pediatrics • Primary Care • Psychiatry • Rheumatology • Urology
- Website
-
http://www.HCPLive.com
External link for HCPLive
- Industry
- Media Production
- Company size
- 2-10 employees
- Headquarters
- Cranbury, NJ
- Type
- Privately Held
- Founded
- 1957
- Specialties
- Managed Care, primary care, family medicine, Healthcare news, Internal Medicine, Medicine, Medical News, FDA News, and Cardiology
Locations
-
Primary
2 Clarke Drive
Suite 100
Cranbury, NJ 08512, US
Employees at HCPLive
Updates
-
Article of the Week: Treatment with deuruxolotinib (Leqselvi; SUN PHARMA) 8 mg led to 95% of patients with alopecia areata reporting significant hair satisfaction improvement over 24 weeks. These pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials were presented at the European Academy of Dermatology and Venereology Congress 2024 by Arash Mostaghimi, MD, MPA, MPH. #Dermatology #EADV2024
Deuruxolitinib Twice-Daily Improves Hair Satisfaction Among Patients with Alopecia Areata
HCPLive on LinkedIn
-
Did you know even dermatology's leading ladies suffer from #ImposterSyndrome? In the latest episode of #TheMedicalSisterhood, Mona Shahriari, MD, FAAD, of Yale Department of Dermatology & Central Connecticut Dermatology, is joined by Tina Bhutani, MD, MAS, of University of California, San Francisco, for a powerful conversation about imposter syndrome and its impact on women in medicine. From personal stories to practical strategies, they dive into how self-doubt can affect professional confidence and share tips on overcoming these challenges. Catch the full conversation on HCPLive! https://lnkd.in/eZe5XV3r #WomenInMedicine #Dermatology
-
New #DontMissABeat! Taher Modarressi, MD, sits down with hosts Muthu Vaduganathan, MD, MPH, of Brigham and Women's Hospital, and Steve Greene, MD, of Duke Clinical Research Institute, to share tips and practical nuggets of wisdom for cardiometabolic health specialists to optimize prescription and adherence to newer therapies. Watch here: https://lnkd.in/eSk-JtCt #HeartFailure #Cardiology #Obesity
-
A team from UCLA, led by postdoctoral researcher Oren Avram, PhD, has developed SLViT, an AI model that converts 3D scans into 2D images, predicting disease risk factors with accuracy. SLViT significantly boosts diagnostic efficiency, matching expert performance while reducing workload by 5,000 times. It excels even with limited training data, paving the way for faster and more reliable diagnoses. Read more: https://lnkd.in/eBagzG9Y #ArtificialIntelligence AI #MedicalInnovation #3DImaging #HealthTech
-
ICYMI: At #ESCCongress24, we spoke with Rahul Aggarwal, MD, of Brigham and Women's Hospital, on the applicability of VICTORION-1 PREVENT, which is a primary prevention trial of inclisiran (Leqvio; Novartis) relative to the US patient population. For more: https://lnkd.in/eU2HDSFr #Cardiology
-
ICYMI: The FDA has granted 510(k) clearance to Elucid for its PlaqueIQ™ imaging analysis software to aid with the diagnosis of cardiovascular disease (CVD). Announced on October 1, 2024, PlaqueIQ is the first cleared non-invasive software capable of objectively quantifying and classifying plaque morphology based on ground-truth histology. Find out more: https://lnkd.in/g8jjHbjd #Cardiology #CVD
-
From #FamilyHeartSummit24: Steve Nissen, MD, of Cleveland Clinic, discusses how the cardiology community needs to learn from previous mistakes in the uptake of LDL-C lowering therapies as it approaches an age of Lp(a)-lowering agents. Learn more: https://lnkd.in/e8ApGWth #Cardiology
-
The FDA has granted Breakthrough Therapy Designation to Sagimet Biosciences denifanstat for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis. The designation is supported by positive data from the phase 2b FASCINATE trial, demonstrating statistically significant improvements with denifanstat relative to placebo on both primary endpoints of MASH resolution without worsening of fibrosis. Find out more, including perspective from Dave Happel, CEO of Sagimet: https://lnkd.in/eh2QvfvY #Hepatology #MASH #MASLD
-
ICYMI Ascendis Pharma has submitted a supplemental Biologics License Application #FDA for TransCon hGH for the treatment of adults with growth hormone deficiency. The sBLA submission was based on results from the Phase 3 foresiGHt trial, demonstrating the superiority of weekly TransCon hGH on primary efficacy and key secondary efficacy endpoints to placebo. Find out more: https://lnkd.in/egZ2vyaB #FDANews #Endocrinology